LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

Начало・Списък с акции・AstraZeneca PLC

AstraZeneca PLC

Затворен

СекторЗдравеопазване

187.25 -1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

186.99

Максимум

188.07

Ключови измерители
By Trading Economics
Приходи	1.6B 3.9B
Продажби	-215M 15B
P/E Средно за сектора	27.887 49.701
EPS	1.29
Дивидентна доходност	1.74
Марж на печалбата	25.602
Служители	96,100
EBITDA	1.1B 5.7B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+15.53% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.74% 2.39%
Следващи печалби	27.07.2026 г.
Следваща дата на екс-дивидент	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.5B 287B
Предишно отваряне	188.57
Предишно затваряне	187.25

Настроения в новините

By Acuity

50%

146 / 345 Класиране в Healthcare

AstraZeneca PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2026 г., 16:28 ч. UTC

Печалби

Correction to AstraZeneca Update

29.04.2026 г., 15:11 ч. UTC

Печалби

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29.04.2026 г., 06:31 ч. UTC

Печалби

AstraZeneca Gets Revenue Boost From Cancer Drugs

21.05.2026 г., 11:06 ч. UTC

Пазарно говорене

AstraZeneca Set for Busy End of Year -- Market Talk

13.05.2026 г., 12:29 ч. UTC

Пазарно говорене

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13.05.2026 г., 11:54 ч. UTC

Пазарно говорене

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1.05.2026 г., 09:31 ч. UTC

Пазарно говорене

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29.04.2026 г., 10:29 ч. UTC

Пазарно говорене

Печалби

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29.04.2026 г., 10:06 ч. UTC

Пазарно говорене

Печалби

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29.04.2026 г., 09:53 ч. UTC

Пазарно говорене

Печалби

AstraZeneca Seems in Fine Health -- Market Talk

29.04.2026 г., 06:05 ч. UTC

Печалби

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29.04.2026 г., 06:04 ч. UTC

Печалби

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29.04.2026 г., 06:04 ч. UTC

Печалби

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29.04.2026 г., 06:03 ч. UTC

Печалби

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29.04.2026 г., 06:03 ч. UTC

Печалби

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29.04.2026 г., 06:02 ч. UTC

Печалби

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29.04.2026 г., 06:01 ч. UTC

Печалби

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29.04.2026 г., 06:01 ч. UTC

Печалби

AstraZeneca Backs 2026 View

29.04.2026 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 1Q Adj EPS $2.58

29.04.2026 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 1Q Rev $15.29B

29.04.2026 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 1Q Pretax Pft $3.91B

29.04.2026 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 1Q Oper Pft $4.25B

29.04.2026 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 1Q Net Pft $3.08B

29.04.2026 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 1Q EPS $1.97

27.04.2026 г., 10:48 ч. UTC

Пазарно говорене

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10.04.2026 г., 11:57 ч. UTC

Пазарно говорене

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10.04.2026 г., 10:26 ч. UTC

Пазарно говорене

Печалби

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2.04.2026 г., 09:16 ч. UTC

Пазарно говорене

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27.03.2026 г., 10:40 ч. UTC

Пазарно говорене

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27.03.2026 г., 10:17 ч. UTC

Пазарно говорене

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

AstraZeneca PLC Прогноза

Ценова цел

By TipRanks

15.53% нагоре

12-месечна прогноза

Среден 216.074 USD 15.53%

Висок 249.984 USD

Нисък 151.872 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за AstraZeneca PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на AstraZeneca PLC през последните 3 месеца.

Настроение

By Acuity

146 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.